Intellia Therapeutics, Inc.

NasdaqGM:NTLA Stock Report

Market Cap: US$1.7b

Intellia Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:NTLA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
22 Jul 26SellUS$91,249Edward DulacIndividual8,111US$11.25
01 Jul 26SellUS$44,316Michael DubeIndividual2,641US$16.78
02 Mar 26SellUS$8,364Eliana ClarkIndividual607US$13.78
02 Mar 26SellUS$16,688James BastaIndividual1,211US$13.78
05 Jan 26BuyUS$1,402,500Fred CohenIndividual150,000US$9.35
05 Jan 26SellUS$58,751Edward DulacIndividual6,379US$9.21
05 Jan 26SellUS$95,756James BastaIndividual10,397US$9.21
05 Jan 26SellUS$314,485John LeonardIndividual34,146US$9.21
05 Jan 26SellUS$27,529Michael DubeIndividual2,989US$9.21
05 Jan 26SellUS$87,633Eliana ClarkIndividual9,515US$9.21
05 Jan 26SellUS$78,359Birgit SchultesIndividual8,508US$9.21
05 Jan 26SellUS$109,627David LebwohlIndividual11,903US$9.21
01 Oct 25SellUS$539Birgit SchultesIndividual31US$17.38
01 Oct 25SellUS$32,518Michael DubeIndividual1,871US$17.38
20 Aug 25BuyUS$1,003,000William ChaseIndividual100,000US$10.03

Insider Trading Volume

Insider Buying: NTLA insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of NTLA?
Owner TypeNumber of SharesOwnership Percentage
Private Companies583,6890.418%
Individual Insiders2,009,1871.44%
Public Companies3,702,9952.65%
General Public20,681,24914.8%
Institutions112,745,15780.7%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 30.2%.

Top Shareholders

Top 25 shareholders own 66.97% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11%
BlackRock, Inc.
15,409,023US$184.0m26.8%no data
10.4%
ARK Investment Management LLC
14,509,247US$173.2m2.13%1.0%
6.61%
State Street Investment Management
9,234,987US$110.3m33.4%no data
4.45%
Vanguard Portfolio Management, LLC
6,223,325US$74.3m0%no data
4.17%
Vanguard Capital Management, LLC
5,832,208US$69.6m0%no data
4.1%
D. E. Shaw & Co., L.P.
5,728,177US$68.4m7.45%0.05%
3.37%
Two Sigma Investments, LP
4,705,901US$56.2m74.4%0.04%
2.65%
Regeneron Pharmaceuticals, Inc.
3,702,995US$44.2m0%no data
2.13%
UBS Asset Management AG
2,973,444US$35.5m171%no data
2.07%
Amova Asset Management Co., Ltd.
2,897,529US$34.6m46.9%0.01%
2.04%
Geode Capital Management, LLC
2,851,472US$34.0m5.76%no data
1.66%
Dimensional Fund Advisors LP
2,318,110US$27.7m20%no data
1.47%
FMR LLC
2,058,508US$24.6m17.5%no data
1.37%
Contrarius Investment Management Ltd.
1,911,839US$22.8m168%1.21%
1.27%
Jupiter Fund Management Plc
1,781,063US$21.3m71.6%0.04%
1.15%
Voloridge Investment Management, LLC
1,611,534US$19.2m-7.25%0.07%
1.09%
Morgan Stanley
1,519,623US$18.1m-19.4%no data
1%
Arrowstreet Capital, Limited Partnership
1,397,243US$16.7m0%0.01%
0.83%
The Goldman Sachs Group, Inc.
1,159,497US$13.8m0%no data
0.81%
Bank of America Corporation
1,134,026US$13.5m12.7%no data
0.72%
Stifel Asset Management Corp.
1,012,706US$12.1m0%0.01%
0.69%
Northern Trust Global Investments
966,293US$11.5m10.7%no data
0.68%
John Leonard
943,225US$11.3m-14.7%no data
0.67%
Charles Schwab Investment Management, Inc.
941,285US$11.2m0%no data
0.54%
Connor, Clark & Lunn Investment Management Ltd.
748,636US$8.9m188%0.02%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/09 20:47
End of Day Share Price 2026/08/07 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Intellia Therapeutics, Inc. is covered by 33 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Brian SkorneyBaird
William PickeringBernstein